Eli Lilly completes acquisition of Centessa Pharmaceuticals
Share
- Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage biotech focused on orexin receptor 2 agonists.
- The deal adds Centessa’s pipeline targeting narcolepsy and other sleep-wake disorders to Lilly’s portfolio.
- Lilly stated it will advance Centessa’s clinical programs to address significant unmet needs in sleep and wakefulness conditions.
Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders.
Lilly plans to advance Centessa’s clinical portfolio to address unmet needs in conditions driven by disrupted sleep and wakefulness.
The acquisition strengthens Lilly’s presence in neuroscience and sleep medicine.
Eli Lilly will integrate Centessa’s orexin receptor 2 agonist programs into its broader development pipeline.
Centessa brings potential new therapies aimed at treating narcolepsy and related sleep-wake disorders through targeted orexin pathway modulation.
Frequently asked questions
More from United States
Arm Q2 revenue hits $1.44B as AI chip demand surges
Qualcomm Q4 earnings beat estimates as auto sales jump 89%
Melco Resorts Q3 revenue falls 10% to $1.17 billion
Emerson Q4 revenue accelerates 7% to $5.2 billion
Flowco Q3 revenue revs up 46% to $258.6 million
Clear secure Q3 revenue hits $292.9M as top line expands 27.8%
